B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)

D. L. Petersen, T. Krejsgaard, J. Berthelsen, S. Fredholm, A. Willerslev-Olsen, N. A. Sibbesen, C. M. Bonefeld, M. H. Andersen, C. Francavilla, J. V. Olsen, T. Hu, M. Zhang, M. A. Wasik, C. Geisler, A. Woetmann, N. Odum

Research output: Contribution to journalLetterpeer-review

36 Scopus citations
Original languageEnglish
Pages (from-to)2109-2112
Number of pages4
JournalLeukemia
Volume28
Issue number10
DOIs
StatePublished - Oct 1 2014

Keywords

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Dasatinib
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lymphoma, T-Cell, Cutaneous/genetics
  • Mice
  • Neoplasm Transplantation
  • Neoplasms/metabolism
  • Phosphorylation
  • Pyrimidines/administration & dosage
  • Thiazoles/administration & dosage
  • src-Family Kinases/metabolism

Fingerprint

Dive into the research topics of 'B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)'. Together they form a unique fingerprint.

Cite this